Lucitanib

Short description: Chemical compound

Lucitanib

Clinical data
Other names| CO-3810, E-3810
Routes of
administration| By mouth
ATC code|

* None

Legal status
Legal status|

* Investigational

Pharmacokinetic data
Elimination half-life| 31–40 hrs
Identifiers

IUPAC name

* 6-({7-[(1-Aminocyclopropyl)methoxy]-6-methoxy-4-quinolinyl}oxy)-N-methyl-1-naphthamide

CAS Number|

* 1058137-23-7

PubChem CID|

* 25031915

ChemSpider|

* 28189586

UNII|

* PP449XA4BH

KEGG|

* D11762

ChEBI|

* CHEBI:65209

ChEMBL|

* ChEMBL2180605

Chemical and physical data
Formula| C26H25N3O4
Molar mass| 443.503 g·mol−1
3D model (JSmol)|

* Interactive image

SMILES

* CNC(=O)c1cccc2c1ccc(c2)Oc3ccnc4c3cc(c(c4)OCC5(CC5)N)OC

InChI

* InChI=1S/C26H25N3O4/c1-28-25(30)19-5-3-4-16-12-17(6-7-18(16)19)33-22-8-11-29-21-14-24(23(31-2)13-20(21)22)32-15-26(27)9-10-26/h3-8,11-14H,9-10,15,27H2,1-2H3,(H,28,30)

* Key:CUDVHEFYRIWYQD-UHFFFAOYSA-N

Lucitanib (INN) is a drug that is being investigated by Clovis Oncology in clinical trials for the treatment of advanced solid tumours[1] including metastatic breast cancer.[2] It is a protein kinase inhibitor that blocks the VEGF receptors 1, 2 and 3, as well as the fibroblast growth factor receptors 1 and 2, and the platelet-derived growth factor receptors alpha and beta.[1]

## References

1. ↑ 1.0 1.1 "Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors". Annals of Oncology 25 (11): 2244–51. November 2014. doi:10.1093/annonc/mdu390. PMID 25193991.
2. ↑ Clinical trial number NCT02053636 for "A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer (FINESSE)" at ClinicalTrials.gov

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/Lucitanib. Read more

|

Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Lucitanib&oldid=537480"
*[CID]: Compound ID